Gold Surges 3%; Bristol-Myers Squibb Earnings Top Views

Aerska Appoints Laura Sepp-Lorenzino to Scientific Advisory Board

Aerska, a biotechnology company developing RNA medicines for CNS diseases through its antibody-oligonucleotide conjugate (AOC) platform, has appointed Laura Sepp-Lorenzino to its Scientific Advisory Board. Sepp-Lorenzino brings over 30 years of experience in genetic medicines and nucleic acid therapies, previously serving as Chief Scientific Officer at Intellia Therapeutics and leading nucleic acid programs at Vertex Pharmaceuticals.

Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics

The global oligonucleotide therapeutics market is projected to grow from USD 7.7 billion in 2025 to USD 72.1 billion by 2035, expanding at a 23.4% CAGR. Growth is driven by advances in RNA-based medicine, targeted delivery technologies, expanding applications beyond rare diseases into chronic and metabolic conditions, and increasing regulatory approvals. Antisense oligonucleotides lead the market at 39.9% share, while subcutaneous administration dominates at 56.4%. North America commands 57.9% market share.

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $455 price target.

Reported Earlier, Alnylam Highlights AMVUTTRA Results And New RNAi Approach For High Blood Pressure

Bristol Myers Squibb’s Psoriatic Arthritis Pill Shows Durable Efficacy After Two Years

Bristol Myers Squibb (BMY) 2-year Phase 3 data shows Sotyktu maintains durable efficacy and safety in active psoriatic arthritis.

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

With traditional retirement income sources like bonds and Social Security proving inadequate, the article recommends dividend-paying stocks from high-quality companies as a reliable income alternative. Three stocks are highlighted: Bristol Myers Squibb (3.96% yield), Fulton Financial (3.24% yield), and InvenTrust Properties Corp. (3.24% yield), all offering steady dividend growth to help offset inflation.